Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

tosedostat

Known as: 2-(2-(hydroxy(hydroxycarbamoyl)methyl)-4-methylpentanoylamino)-2-phenylethanoic acid cyclopentyl ester, Aminopeptidase inhibitor CHR-2797, Cyclopentyl (2S)-2-{(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4- methylpentanamido}-2-phenylacetate 
A proprietary orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. Aminopeptidase inhibitor CHR… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Tosedostat, an oral aminopeptidase inhibitor, has synergy with cytarabine and hypomethylating agents. We performed a Phase II… Expand
2015
2015
New anti‐malarial treatments are desperately required to face the spread of drug resistant parasites. Inhibition of… Expand
2013
2013
BACKGROUND Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elderly… Expand
2013
2013
ABSTRACT Candida species are the cause of 60% of all mycoses in immunosuppressed individuals, leading to ∼150,000 deaths annually… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2013
2013
Microfluidic systems show great promise for single-cell analysis; however, as these technologies mature, their utility must be… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
Aminopeptidase enzyme inhibition is thought to deplete the free intracellular amino acids needed by malignant cells for growth… Expand
  • table 1
  • figure 1
  • figure 2
Highly Cited
2010
Highly Cited
2010
PURPOSE To identify the maximum-tolerated dose (MTD) and to evaluate the antileukemic activity of tosedostat (formerly CHR-2797… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2010
2010
Background:This Phase Ib dose-escalating study investigated safety, maximum tolerated dose (MTD), dose-limiting toxicity (DLT… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2009
2009
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary therapeutic activity… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
1992
1992
Hippocampal CA1 pyramidal cell neurons are sensitized to depolarization by L-2-amino-4-phosphonobutanoic acid (L-AP4) following… Expand